Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 1 · ActiveModality: antibody drug conjugate (ADC)
Aliases SYS6002
Target Nectin-4
Partnerships Licensed from CSPC Megalith Biopharmaceutical Co. Ltd. (Feb 2023); Corbus holds U.S., Canada, EU/EFTA, U.K., Australia rights. CSPC is investigating CRB-701 in a Phase 3 cervical cancer trial in China.
Head and neck squamous cell carcinoma (HNSCC)(Phase 1)
Catalysts
— September 2026
— Q1 2027
Status note Next-generation ADC targeting Nectin-4 with MMAE payload. Phase 1/2 Western study (U.S. and Europe) in advanced Nectin-4-expressing solid tumors ongoing; dose expansion ongoing; PD-1 combination arm with Keytruda (pembrolizumab) began dosing Jun 2025. Fast Track: r/r metastatic cervical cancer (Dec 2024); recurrent/metastatic HNSCC previously treated with platinum + anti-PD(L)-1 (Sep 2025). FDA cleared registrational study TEMPO-1 in 2L OPSCC.
CRB-913
Phase 1 · ActiveModality: small molecule (oral CB1 inverse agonist)
Status note Orally delivered, highly peripherally restricted cannabinoid type-1 (CB1) inverse agonist for obesity. Phase 1a SAD/MAD completed Dec 2025. Phase 1b dose-range finding study CANYON-1 (240 U.S. patients, 4 arms, 12 weeks treatment + 4 weeks follow-up) initiated Dec 2025; last patient completed last clinical visit Aug 2026.
CRB-601
Phase 1 · TerminatedModality: monoclonal antibody
Target αvβ8 integrin
Partnerships Licensed from The Regents of the University of California (May 2021); exclusive license to αvβ8 antibody patents.
Indications
Solid tumors(Phase 1)
Status note Anti-αvβ8 integrin monoclonal antibody that blocks activation of latent TGFβ. Phase 1 dose escalation study completed; program deprioritized — no additional patients will be enrolled.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.